Financial Report Forecast | COVID-19 Product Revenue Continues to Decline Where is PFE.US (PFE.US)'s New Growth Engine?
Pfizer is scheduled to announce the first quarter of 2024 results in advance of the US stock market on May 1.
Zhitong Finance00:25 ET
WHO Picks JN.1 Variant for Next Set of COVID Vaccines
Seeking AlphaApr 27 14:11 ET
Eliminates hundreds of treatments! Pfizer (PFE.US) gene therapy approved for listing by FDA
Pfizer/PFE.us (Pfizer/PFE.us) announced that the US FDA has approved the single-use gene therapy Beqvez (fidanacogene elaparvovec) it has developed to treat adults with moderate to severe hemophilia B aged 18 or above.
Zhitong FinanceApr 27 04:08 ET
Pfizer Options Spot-On: On April 26th, 118.91K Contracts Were Traded, With 3.21 Million Open Interest
On April 26th ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 118.91K options for the day, of which put options accounted for 37.64% of the total transactions, and call
moomoo NewsApr 26 16:30 ET
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Health care stocks were advancing late Friday afternoon, with the NYSE Health Care Index adding 0.2% and the Health Care Select Sector SPDR Fund (XLV) up 0.1%. The iShares Biotechnology ETF (IBB) rose
MT NewswiresApr 26 15:57 ET
Express News | NYSE Order Imbalance 3209310.0 Shares on Sell Side
ReutersApr 26 15:50 ET
Pfizer is the first gene therapy approved in the US! Treating hemophilia B
On Friday, April 26, the US Food and Drug Administration (FDA) announced that it has officially approved a new drug called Beqvez developed by Pfizer to treat hemophilia B. According to reports, this is the first gene therapy drug approved by Pfizer in the US market. Hemophilia B is a rare hereditary bleeding disorder that mainly affects men. The cause is a lack or complete absence of a blood clotting protein called factor IX in the patient's body. This lack of protein makes it difficult for blood to clot, making patients prone to bruising and prolonged bleeding time. In severe cases, patients can even experience ignorance
wallstreetcnApr 26 15:24 ET
More Than Half of the S&P 500 Names That Reported Results This Week Beat Top and Bottom Line - Earnings Scorecard
Seeking AlphaApr 26 15:11 ET
FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
Friday, the FDA approved Pfizer Inc's (NYSE:PFE) Beqvez (fidanacogene elaparvovec-dzkt) for moderate to severe hemophilia B in adult patients who currently use factor IX (FIX) prophylaxis therapy or h
BenzingaApr 26 14:30 ET
Pfizer (NYSE:PFE) Notches Up on New FDA Approval
TipRanksApr 26 12:33 ET
Options Corner: Pfizer's Options Market Sees Big Money Take Bullish Stance
Deep-pocketed investors have adopted a bullish approach towards Pfizer (NYSE:PFE), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this
BenzingaApr 26 10:22 ET
Pfizer Gains as Gene Therapy Wins FDA Nod
Baystreet.caApr 26 10:03 ET
Pfizer Receives FDA Approval for Bleeding Disorder Treatment -- Barrons.com
By Emily Dattilo Pfizer has received approval from the Food and Drug Administration for a rare genetic bleeding disorder treatment -- the drug-maker's first gene therapy to be approved in the U.S. T
Barron'sApr 26 09:35 ET
Pfizer Hits 11-year Low
Trading EconomicsApr 26 09:30 ET
Sector Update: Health Care Stocks Mixed Premarket Friday
Health care stocks were mixed premarket Friday as the Health Care Select Sector SPDR Fund (XLV) was down 0.3% and the iShares Biotechnology ETF (IBB) was recently up 0.2% Centene (CNC) was up 0.4% aft
MT NewswiresApr 26 09:16 ET
Gear Up for Pfizer (PFE) Q1 Earnings: Wall Street Estimates for Key Metrics
Yahoo FinanceApr 26 09:15 ET
AbbVie (ABBV) Beats Q1 Earnings and Revenue Estimates
Yahoo FinanceApr 26 08:45 ET
Dividend Roundup: MetLife, General Motors, Pfizer, Citigroup, and More
Seeking AlphaApr 26 08:01 ET
UPDATE 1-US FDA Approves Pfizer's Gene Therapy for Rare Bleeding Disorder
Yahoo FinanceApr 26 07:00 ET
Express News | Pfizer Inc: Wholesale Acquisition Cost for a One-Time Dose of Beqvez in the U.S. Is $3.5 Million
ReutersApr 26 06:59 ET
No Data
No Data